• About
  • Contact
  • Resources
  • Book Nook
Donate
  • Featured
  • Commentary
  • Science & News
  • Mainstream
    • Mainstream Prevention
    • Mainstream Treatment
    • Vaccines
    • Repurposed Drugs
  • Integrative
    • Integrative Prevention
    • Integrative Treatments
    • Integrative Recovery
      • Long Haul
  • Controversies
    • Ivermectin
  • Blog
    • Michael Lerner’s Blog
    • Guest Authors
MenuClose
  • Featured
  • Commentary
  • Science & News
  • Mainstream Solutions
    • Mainstream Prevention
    • Mainstream Treatment
    • Vaccines
    • Repurposed Drugs
  • Integrative Therapies
    • Integrative Prevention
    • Integrative Treatments
    • Integrative Recovery
      • Long Haul
  • Controversies
    • Ivermectin
  • Blog
    • Guest Authors
    • Michael Lerner’s Blog
  • About
  • Contact
  • Resources
  • Donate
 — Article Category —

Mainstream Solutions


What Is ‘Paxlovid Rebound’? CDC Warns of COVID-19 Recurrence After Antiviral Treatment

What Is ‘Paxlovid Rebound’? CDC Warns of COVID-19 Recurrence After Antiviral Treatment

by Covid Strategies | Jun 1, 2022 | Featured, Mainstream Treatment, Science & News

The recurring symptoms are usually milder than the initial illness—but you may still be contagious. By Julia Ries  Some patients who have taken Pfizer's Paxlovid medication—an antiviral drug used to prevent severe illness from COVID-19—have experienced a recurrence in...

read more
Rebound COVID Is Just the Start of Paxlovid’s Mysteries

Rebound COVID Is Just the Start of Paxlovid’s Mysteries

by Covid Strategies | May 26, 2022 | Featured, Mainstream Treatment

There’s plenty more to learn about the lifesaving antiviral COVID treatment.   By Rachel Gutman The first data on Paxlovid, out last November, hinted that the COVID antiviral would cut the risk of hospitalization and death by 89 percent. Pundits called the drug...

read more
FDA rebukes Pfizer CEO’s suggestion to take more Paxlovid if COVID-19 symptoms return

FDA rebukes Pfizer CEO’s suggestion to take more Paxlovid if COVID-19 symptoms return

by Covid Strategies | May 5, 2022 | Featured, Mainstream Treatment, Science & News

By Zoey Becker The FDA rebuked Pfizer CEO Albert Bourla’s proposed solution to reports that some patients experienced a relapse of COVID-19 symptoms after treatment with the company's antiviral Paxlovid. After reports said some patients who took Paxlovid rebounded and...

read more
FAMOTIDINE SHOWN TO SIGNIFICANTLY DECREASE COVID SYMPTOMS IN 55-PATIENT RANDOMIZED TRIAL

FAMOTIDINE SHOWN TO SIGNIFICANTLY DECREASE COVID SYMPTOMS IN 55-PATIENT RANDOMIZED TRIAL

by Covid Strategies | Feb 26, 2022 | Featured, Repurposed Drugs

Famotidine, the over-the-counter heartburn drug, pepcid, was shown to significantly decrease COVID symptoms in a 55-patient randomized trial authored by Dr. Tobias Janowitz and published in the BMJ journal Gut February 10, 2022. Famotidine has been...

read more
Honduras Reduced COVID Deaths With Repurposed Drugs, Early Treatment

Honduras Reduced COVID Deaths With Repurposed Drugs, Early Treatment

by Covid Strategies | Feb 11, 2022 | Repurposed Drugs, Science & News

Dr. Fernando Valerio, a critical care doctor in Honduras who co-authored a recent peer-reviewed study indicating the potential of repurposed drugs targeting SARS-CoV-2, shared with Trial Site his experience treating patients in the Central American nation....

read more
Concern as Republicans push to make dubious Covid cure prescriptions easier

Concern as Republicans push to make dubious Covid cure prescriptions easier

by Covid Strategies | Jan 30, 2022 | Controversies, Featured, Ivermectin, Repurposed Drugs

Ivermectin and hydroxychloroquine, the cures in question, have proven to be ineffective in preventing or treating Covid-19 By Eric Berger Republican state lawmakers across the United States have proposed – and in some cases passed – legislation that they say keeps the...

read more
NIAID Sponsored Study: Hyperimmune Intravenous Immunoglobulin & Remdesivir Fails to Beat Remdesivir as COVID-19 Treatment

NIAID Sponsored Study: Hyperimmune Intravenous Immunoglobulin & Remdesivir Fails to Beat Remdesivir as COVID-19 Treatment

by Covid Strategies | Jan 29, 2022 | Mainstream Treatment, Science & News

Recently, an international trial site network known as the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) completed a global study revealing that remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2...

read more
TFF Pharmaceuticals Advancing Niclosamide, an Inhaled COVID-19 Treatment with Potential Activity Against Multiple Variants

TFF Pharmaceuticals Advancing Niclosamide, an Inhaled COVID-19 Treatment with Potential Activity Against Multiple Variants

by Covid Strategies | Jan 28, 2022 | Mainstream Treatment, Science & News

TFF Pharmaceuticals announced it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other respiratory viral diseases. TFF develops...

read more
Paxlovid Cleared for Conditional Use in Europe

Paxlovid Cleared for Conditional Use in Europe

by Covid Strategies | Jan 27, 2022 | Mainstream Treatment, Science & News

Paxlovid, the oral Pfizer treatment for COVID-19, appears headed for emergency use authorization in Europe.  Conditional Marketing Authorization for Paxlovid The European Medical Agency’s (EMA) human medicines committee (CHMP) recommended Pfizer Europe MA EEIG...

read more
University of Calgary Repurposed Drug Breakthrough: Hydroxychloroquine Delays Severe Forms of Multiple Sclerosis

University of Calgary Repurposed Drug Breakthrough: Hydroxychloroquine Delays Severe Forms of Multiple Sclerosis

by Covid Strategies | Jan 24, 2022 | Repurposed Drugs, Science & News

What if a relatively low-cost, repurposed drug could help treat multiple sclerosis (MS), the least treatable of all autoimmune diseases? That could be a distinct possibility now that Dr. Marcus Koch, MD, Ph.D., and Dr. Wee Yong, Ph.D., with Cummings School of Medicine...

read more
Merck Inks Deal with Bangladeshi Pharma to Distribute Molnupiravir to 100+ Countries Targeting Important COVID-19 Antiviral Market

Merck Inks Deal with Bangladeshi Pharma to Distribute Molnupiravir to 100+ Countries Targeting Important COVID-19 Antiviral Market

by Covid Strategies | Jan 23, 2022 | Repurposed Drugs, Science & News

With a great demand for antivirals targeting early-onset COVID-19, Merck inked a sub-licensing deal with one of the largest pharmaceutical companies in Bangladesh to produce Molnupiravir (Lagevrio) for distribution to over 100 nations. The deal, part of the Medicine...

read more
Merck’s COVID-19 pill to be produced by more than two dozen drugmakers

Merck’s COVID-19 pill to be produced by more than two dozen drugmakers

by Covid Strategies | Jan 20, 2022 | Featured, Mainstream Solutions, Mainstream Treatment

BY MONIQUE BEALS Medicines Patent Pool, an organization supported by the U.N., announced on Thursday that over two dozen generic drug makers will soon begin producing Merck's COVID-19 pill to make the treatment more accessible in developing...

read more
Researchers report potential broad-spectrum anti-coronavirus cocktail therapy

Researchers report potential broad-spectrum anti-coronavirus cocktail therapy

by Covid Strategies | Jan 19, 2022 | Featured, Integrative Treatments, Mainstream Treatment

A research team led by Professor Hongzhe Sun, Norman & Cecilia Yip Professor in Bioinorganic Chemistry from the Department of Chemistry, Faculty of Science, the University of Hong Kong (HKU), in collaboration with Dr. Shuofeng Yuan, Assistant Professor from the...

read more
Fauci warns of ‘urgent need’ for super vaccine as other variants emerge

Fauci warns of ‘urgent need’ for super vaccine as other variants emerge

by Covid Strategies | Jan 11, 2022 | Mainstream Prevention, Mainstream Solutions, Mainstream Treatment, Vaccines

New variants will pose continued threat, NIAID chief warns By John Bowden, Megan Sheets Dr Anthony Fauci warned at a Senate committee hearing that the US faced an “urgent need” for a so-called super vaccine that would be more effective at preventing new variants of...

read more
Immunogenicity of COVID-19 BNT162b2 mRNA Vaccine Booster in Patients With Cancer Receiving Active Treatment

Immunogenicity of COVID-19 BNT162b2 mRNA Vaccine Booster in Patients With Cancer Receiving Active Treatment

by Covid Strategies | Jan 10, 2022 | Mainstream Prevention, Mainstream Solutions, Vaccines

By Matthew Stenger In an Israeli single-institution study reported in The Lancet Oncology, Ligumsky et al found that a booster dose of the SARS–CoV-2 Pfizer-BioNTech BNT162b2 mRNA vaccine given in August or September 2021 was immunogenic in patients receiving...

read more
Page 1 of 2912345…1020…»Last »

Address:

Commonweal P.O Box 316 | Bolinas, CA 94924

Latest Covid news in your inbox!

Success!

Subscribe

Search Articles

©2021 CovidStrategies/Commonweal | Site maintained by Mercury Multimedia

Privacy Policy | Home